CML is different than your standard indications, so your second question isn't particularly relevant. It would be ludicrous and stupid to make ariad (or anyone) run a study against Omapro or require a control arm, i.e. placebo. So, yes.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.